Neurologists are excited because a class of once-monthly migraine injections — known as CGRP monoclonal antibodies — has fundamentally changed how they treat a disease that affects roughly 39 million Americans and one billion people worldwide. These shots target the specific protein responsible for migraine pain rather than borrowing drugs designed for blood pressure or seizures, and the results have been striking: patients on erenumab (Aimovig), for instance, report a 50% reduction in severe headache days per month. For a field that spent decades managing migraine with repurposed medications and crossed fingers, that shift feels seismic.
The excitement grew again in August 2025, when the FDA approved fremanezumab (Ajovy) for children as young as six — making it the first and only anti-CGRP therapy cleared for both pediatric and adult episodic migraine prevention in the United States. In clinical trials, 47% of children on fremanezumab cut their migraine days in half, and overall headache days dropped by 63% per month. For parents who have watched their kids miss school and withdraw from activities, that number is not abstract. This article covers how CGRP shots work, how they compare to older treatments, what the latest safety data shows, and what the real-world costs and limitations look like heading into 2026.
Table of Contents
- What Makes Once-Monthly Migraine Shots Different From Older Preventive Treatments?
- How Effective Are CGRP Injections in Real-World Practice?
- What Does the Pediatric Approval Mean for Younger Migraine Patients?
- How Do the Four FDA-Approved CGRP Injections Compare?
- What Are the Safety Concerns Neurologists Are Watching?
- The Rise of Oral CGRP Antagonists and What They Mean for Injection-Based Treatments
- Where Migraine Treatment Is Headed
- Conclusion
- Frequently Asked Questions
What Makes Once-Monthly Migraine Shots Different From Older Preventive Treatments?
Traditional migraine prevention relied on drugs that were never designed for headaches. Beta-blockers like propranolol were built for heart conditions. Topiramate was an anticonvulsant. Amitriptyline was an antidepressant. Doctors prescribed them because they happened to reduce migraine frequency in some patients, but the side effects — weight gain, cognitive fog, fatigue, dizziness — drove people away in droves. Only 25% of patients on daily oral preventatives are still taking them at six months, and just 14% remain at twelve months. That is not a compliance problem. That is a tolerability problem.
CGRP monoclonal antibodies changed the equation by going after calcitonin gene-related peptide, a protein that plays a direct role in migraine signaling. When CGRP floods the trigeminal nerve system during a migraine attack, it triggers inflammation and pain. Drugs like aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab) either block CGRP itself or its receptor, interrupting the cascade before it starts. The mechanism is precise, and because these antibodies do not cross the blood-brain barrier in meaningful amounts, they tend to produce fewer systemic side effects than the older oral drugs. The practical difference matters too. Instead of remembering a daily pill — or two, or three — patients give themselves a single subcutaneous injection once a month. Ajovy also offers a quarterly dosing option. Vyepti (eptinezumab) is administered as an intravenous infusion every three months in a clinical setting. For people whose migraines have made daily routines unpredictable, the simplicity of one shot a month removes a layer of cognitive burden that the older regimens never could.
How Effective Are CGRP Injections in Real-World Practice?
Clinical trials produce clean numbers under controlled conditions, so the question that matters most to practicing neurologists is whether those results hold up in actual patients — people with comorbidities, inconsistent schedules, and complicated medication histories. The answer, increasingly, is yes. A real-world observational study of 1,105 adult patients on galcanezumab (Emgality) confirmed that the efficacy seen in trials translates to everyday clinical settings. Patients who had failed multiple prior preventatives still experienced meaningful reductions in monthly migraine days. The data on eptinezumab (Vyepti) tells a similar story. In a 2025 real-world study focused specifically on treatment-resistant migraine patients — the hardest cases — 41% achieved at least a 50% reduction in monthly migraine days, and 62% achieved at least a 30% reduction.
These are patients who had already tried and failed other options. For neurologists accustomed to delivering bad news, being able to offer something that works for resistant cases has genuinely shifted the tone of clinic visits. However, “effective” does not mean “effective for everyone.” Roughly half of patients in most trials do not reach the 50% response threshold, and some see little to no benefit. There is currently no reliable biomarker or test to predict who will respond to which CGRP antibody. In practice, neurologists often try one agent for three to six months before switching to another. That trial-and-error period can feel discouraging for patients, and it is worth setting expectations honestly from the start. These drugs are a major step forward, but they are not a cure.
What Does the Pediatric Approval Mean for Younger Migraine Patients?
Migraine in children has been one of the more frustrating corners of neurology. Kids lose school days, drop out of sports, and develop anxiety about when the next attack will hit, yet until recently the preventive options available to them were even more limited than those for adults. Most pediatric migraine treatment involved off-label use of adult medications at lower doses, with side effect profiles that made parents and physicians understandably cautious. The FDA’s August 2025 approval of Ajovy (fremanezumab) for children aged six and older who weigh at least 45 kilograms changed that landscape. The approval was based on clinical trial data showing that 47% of pediatric patients achieved a 50% or greater reduction in monthly migraine days, with overall headache days dropping by 63%.
The dosing is the same as for adults — a 225 mg subcutaneous injection once a month. Researchers at Cincinnati Children’s Hospital, one of the key study sites, noted that these results were consistent with what had been seen in adult populations, which is not always the case when drugs cross the age divide. this approval matters beyond the numbers. It signals to the pediatric neurology community that migraine-specific treatments can be developed and tested in children, not just handed down from adult medicine. It also gives families a concrete option backed by pediatric trial data rather than extrapolation. That said, long-term safety data in children is still limited, and clinicians will need to monitor patients over years to build a fuller picture of how these drugs behave in developing bodies.
How Do the Four FDA-Approved CGRP Injections Compare?
Choosing between CGRP monoclonal antibodies involves weighing mechanism, dosing, route, and cost. Aimovig (erenumab) was the first to receive FDA approval in May 2018 and works by blocking the CGRP receptor rather than the CGRP molecule itself. Ajovy (fremanezumab) and Emgality (galcanezumab) both target the CGRP protein directly, with Ajovy offering the flexibility of monthly or quarterly subcutaneous dosing. Vyepti (eptinezumab) is the outlier — it is given as an intravenous infusion every three months in a healthcare facility, which eliminates the need for self-injection but requires clinic visits. Cost is a significant factor and varies enough to influence decisions. Annual costs for CGRP injections run approximately $7,000 per year.
Per dose, Aimovig costs roughly $750 to $812, Ajovy runs about $689 to $750, and Emgality is approximately $764. Vyepti, because it is an IV infusion, costs around $2,004 per vial. Insurance coverage varies widely, and many plans require patients to fail two or three older preventative medications before approving a CGRP antibody. Manufacturer savings programs can reduce out-of-pocket costs, but navigating the prior authorization process remains one of the most common complaints neurologists hear from patients. From an efficacy standpoint, head-to-head trials between these agents are limited, and no single CGRP antibody has emerged as definitively superior. The practical tradeoff comes down to lifestyle: patients who want minimal medical contact may prefer a monthly self-injection at home, while those who struggle with adherence or needle anxiety might benefit from Vyepti’s quarterly infusion schedule supervised by a nurse. Neurologists generally select based on insurance formulary, patient preference, and whether the patient has any contraindications.
What Are the Safety Concerns Neurologists Are Watching?
CGRP antibodies have a generally favorable safety profile compared to older preventatives, but they are not without risks, and the picture continues to evolve. In March 2025, the FDA updated safety labeling for all CGRP monoclonal antibodies and the related class of oral gepants to include potential risks of developing or worsening hypertension and Raynaud’s phenomenon. Raynaud’s causes blood vessels in the fingers and toes to narrow excessively in response to cold or stress, and since CGRP plays a role in vasodilation, blocking it may reduce the body’s ability to keep peripheral circulation open. For patients with a history of cardiovascular disease, uncontrolled high blood pressure, or Raynaud’s, this labeling change is not trivial. Neurologists are now more carefully screening for vascular risk factors before initiating CGRP therapy.
The concern is not that these events are common — large-scale trial data suggests they are relatively infrequent — but that CGRP is active throughout the cardiovascular system, and long-term blockade in vulnerable patients warrants monitoring that did not previously seem necessary. There is also the question of what happens when patients stop these medications. Some patients report rebound increases in migraine frequency after discontinuation, though this has not been systematically studied to the same degree as efficacy. Additionally, because monoclonal antibodies have long half-lives, any adverse effects that do develop cannot be quickly reversed by simply stopping the drug — the antibody remains in the system for weeks. This is the flip side of the once-monthly convenience: sustained action means sustained exposure, for better or worse.
The Rise of Oral CGRP Antagonists and What They Mean for Injection-Based Treatments
Not every migraine patient wants an injection, and the pharmaceutical industry has responded with oral CGRP antagonists known as gepants. Atogepant (Qulipta), manufactured by AbbVie, is a daily oral pill approved for episodic and chronic migraine prevention. It is projected to generate $766 million in global revenue in 2026, reflecting strong demand for a non-injectable CGRP option.
For patients who are needle-averse or whose insurance will not cover monoclonal antibodies, oral gepants represent a meaningful alternative within the same mechanistic family. However, oral gepants reintroduce the daily adherence challenge that monthly injections were designed to solve. They also carry their own side effect considerations, including the same March 2025 FDA labeling update regarding hypertension and Raynaud’s. Neurologists increasingly view the CGRP landscape as a menu rather than a hierarchy — injections for patients who value convenience and proven long-term data, oral options for those who prefer pills, and IV infusions for those who benefit from supervised quarterly dosing.
Where Migraine Treatment Is Headed
The broader trajectory in migraine medicine points toward greater precision. Researchers are investigating biomarkers that could predict which patients will respond to CGRP blockade, potentially eliminating the current trial-and-error approach. Newer targets beyond CGRP — including pituitary adenylate cyclase-activating peptide (PACAP) and its receptors — are in early clinical development and could expand options for the patients who do not respond to current therapies.
For the brain health community, the CGRP story also has implications beyond migraine. Chronic migraine has been linked to increased risk of white matter lesions, cognitive complaints, and in some studies, modestly elevated dementia risk over decades. Whether effective migraine prevention through CGRP blockade reduces those long-term neurological consequences is an open question — and one that neurologists are watching closely as the first generation of CGRP-treated patients moves through middle age and beyond.
Conclusion
The arrival of once-monthly CGRP migraine injections represents one of the most meaningful advances in headache medicine in decades. With four FDA-approved options, a new pediatric indication, and growing real-world evidence confirming trial results, neurologists finally have targeted tools that match the biology of the disease. The extension of fremanezumab to children as young as six has opened a door that pediatric neurologists have been waiting on for years.
That said, these treatments are not perfect. They do not work for everyone, they cost roughly $7,000 per year, insurance access remains inconsistent, and emerging safety signals around blood pressure and Raynaud’s phenomenon require ongoing vigilance. Patients considering CGRP therapy should have a frank conversation with their neurologist about expectations, costs, and monitoring — and should understand that finding the right treatment may take more than one attempt. The progress is real, but so are the limitations.
Frequently Asked Questions
How quickly do CGRP migraine injections start working?
Most patients begin to notice a reduction in migraine frequency within the first month, though full benefit may take three to six months. Eptinezumab (Vyepti), given by IV, has shown some effects within the first week after infusion, likely due to its rapid onset of action via intravenous delivery.
Can I take a CGRP injection if I am already on a daily migraine preventive?
Yes. Many neurologists initiate CGRP antibody therapy alongside existing preventatives and then taper the older medication if the injection proves effective. There are no major drug interactions between CGRP monoclonal antibodies and common oral preventatives like topiramate or amitriptyline.
Are CGRP injections safe during pregnancy?
There is insufficient data to confirm safety during pregnancy. Most neurologists discontinue CGRP antibodies before conception or as soon as pregnancy is confirmed. Because monoclonal antibodies have long half-lives, they should ideally be stopped several months before a planned pregnancy.
What happens if I stop taking the injection?
Migraines typically return to their previous frequency over weeks to months after discontinuation, though some patients report sustained improvement even after stopping. There is no formal withdrawal syndrome, but rebound worsening has been reported anecdotally.
Will my insurance cover a CGRP injection?
Coverage varies by plan. Most commercial insurers and Medicare Part D plans cover at least one CGRP antibody, but nearly all require prior authorization and documentation that the patient has tried and failed two or more traditional preventatives. Manufacturer copay assistance programs can reduce costs significantly for commercially insured patients.
